hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06366022, orgStudyIdInfo id: Warsaw.06, briefTitle: Evaluation of the Treatment of Multiple Gingival Recession Using Modified Coronally Advanced Tunnel With Subepithelial Connective Tissue Graft Depending on the Positioning of the Graft, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-30, primaryCompletionDateStruct date: 2024-05-30, completionDateStruct date: 2024-05-30, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Medical University of Warsaw, class: OTHER, descriptionModule briefSummary: Microsurgical coronally advanced tunnel procedures using subepithelial connective tissue grafts (sCTG) are predictable for healing of multiple adjacent type 1 and 2 gingival recessions (RT1 and RT2). In order to reduce patient morbidity and enhance periodontal wound healing with sCTG can be used. The aim of this study is to compare the results of the modified tunneling technique with subepithelial connective tissue graft in gingival recessions placed with the inner side towards the flap cover graft and the outer side towards the flap cover graft., conditionsModule conditions: Gingival Recession, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: The tunnel technique for root coverage with CTG with inner side of the graft, interventions name: The tunnel technique for root coverage with CTG with outer side of the graft, outcomesModule primaryOutcomes measure: Clinical attachment level (CAL), primaryOutcomes measure: Recession height (RH), primaryOutcomes measure: Recession width (RW), primaryOutcomes measure: Width of keratinized tissue (KTW), primaryOutcomes measure: Thickness of keratinized tissue (GT, primaryOutcomes measure: Average recession coverage (ARC), primaryOutcomes measure: Complete recession coverage, secondaryOutcomes measure: Probing pocket depth (PPD), secondaryOutcomes measure: Root coverage esthetic score (RES), secondaryOutcomes measure: Post surgical pain and swelling, secondaryOutcomes measure: Patient's satisfaction with treatment, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Department of Periodontology and Oral Mucosa Diseases, Medical University of Warsaw, status: RECRUITING, city: Warsaw, state: MAzowsze, zip: 00-246, country: Poland, contacts name: Bartłomiej Górski, PhD, role: CONTACT, phone: 48225022099, geoPoint lat: 52.22977, lon: 21.01178, hasResults: False
protocolSection identificationModule nctId: NCT06366009, orgStudyIdInfo id: Warsaw Study, briefTitle: Assessment of Patients With Drug-resistant Temporal Lobe Epilepsy With EEG Extended With Intra-auricular Electrodes, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-08, primaryCompletionDateStruct date: 2024-07-31, completionDateStruct date: 2024-07-31, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Przemyslaw Kunert, class: INDUSTRY, collaborators name: NaoX Technologies, collaborators name: Warsaw Medical University Clinical Center, collaborators name: Departments and Clinics of Emergency Medicine of the Medical University of Gdańsk, descriptionModule briefSummary: The study aims to evaluate the effectiveness of long-term video EEG monitoring using 10-20 electrodes extended with intra-auricular electrodes in locating the seizure onset zone and interictal epileptiform discharges (IEDs) in patients with temporal lobe epilepsy (TLE) and nontemporal lobe epilepsy (non-TLE)., conditionsModule conditions: Epilepsy, conditions: Focal Epilepsy, conditions: Drug Resistant Epilepsy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: NaoX in-ear EEG system, outcomesModule primaryOutcomes measure: determination of the starting point of focal temporal epileptic seizures, secondaryOutcomes measure: Identification of subgroups of epileptic patterns, secondaryOutcomes measure: Assessment of ease-of-use and comfort of use of the NAOX in-ear EEG system by patients and the EEG technician, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Kliniki Neurochirurgii CSK UCK WUM, city: Warsaw, country: Poland, contacts name: Przemysław Kunert, Prof., role: CONTACT, contacts name: Maja Kopytek-Beuzen, Dr., role: CONTACT, geoPoint lat: 52.22977, lon: 21.01178, hasResults: False
protocolSection identificationModule nctId: NCT06365996, orgStudyIdInfo id: Core set geriatric ICF, briefTitle: Development and Validation of the Polish Geriatric Core Set., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2025-12-15, completionDateStruct date: 2025-12-15, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: University of Rzeszow, class: OTHER, descriptionModule briefSummary: Population ageing is a global problem. With ageing, involutionary changes and multimorbidity increase, leading to limitations in the performance of daily activities and disability. Proposed by the World Health Organisation (WHO), the geriatric core set is a set of categories of the International Classification of Functioning, Disability and Health (ICF) that allows for a comprehensive assessment of a person of geriatric age. In Poland, the geriatric core set has not yet been adapted and validated. Therefore, the aim of this study is the cultural adaptation and validation of the Polish version of the ICF-based categorical profile for the assessment of older people., conditionsModule conditions: Aging, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 800, type: ESTIMATED, outcomesModule primaryOutcomes measure: ICF Geriatric core set, secondaryOutcomes measure: Sociodemographic data of the sample, secondaryOutcomes measure: Disability - WHODAS 2.0 v 36 item, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Rzeszow, city: Rzeszów, state: Podkarpacie, zip: 35-959, country: Poland, contacts name: Agnieszka Sozańska, professor, role: CONTACT, phone: 530172857, email: asozanska@ur.edu.pl, geoPoint lat: 50.04132, lon: 21.99901, hasResults: False
protocolSection identificationModule nctId: NCT06365970, orgStudyIdInfo id: HCC 23-056, briefTitle: Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-31, primaryCompletionDateStruct date: 2026-05-31, completionDateStruct date: 2027-05-31, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Ibrahim Halil Sahin, class: OTHER, collaborators name: GlaxoSmithKline, descriptionModule briefSummary: The second line of therapy for patients with MSI-H CRC who experience disease progression on anti-PD1 based therapies is not well defined and there is an unmet need for research for patients with anti-PD1 refractory MSI-H CRC. This study will examine the combination of niraparib and dostarlimab for a synergistic antitumor effect for patients with MSI-H CRC., conditionsModule conditions: MMR-D/MSI-H Colorectal Cancers, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Niraparib, interventions name: Dostarlimab, outcomesModule primaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Adverse Events Related to Treatment, secondaryOutcomes measure: Progression-free Survival (PFS), secondaryOutcomes measure: Duration of Response (DoR), secondaryOutcomes measure: Overall Survival (OS), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: UPMC Hillman Cancer Center, city: Pittsburgh, state: Pennsylvania, zip: 15232, country: United States, contacts name: Debra Diecks, MSN, role: CONTACT, phone: 412-623-8364, email: diecksda@upmc.edu, contacts name: Ibrahim Sahin, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 40.44062, lon: -79.99589, hasResults: False
protocolSection identificationModule nctId: NCT06365957, orgStudyIdInfo id: BSERE24-APP001-FED, briefTitle: Acute Effects of Exercise Combined With Ketone Ester Supplement, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-04, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: University of Macau, class: OTHER, descriptionModule briefSummary: To examine the acute changes in cardiometabolic and neurocognitive outcomes in response to exercise combined with ketone ester supplement in overweight/obese adults., conditionsModule conditions: Overweight and Obesity, conditions: Cognitive Change, conditions: Ketoses, Metabolic, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Ketone monoester supplementation, interventions name: High-intensity interval exercise, interventions name: Moderate-intensity continuous exercise, interventions name: Placebo, outcomesModule primaryOutcomes measure: Maximal Oxygen Uptake, primaryOutcomes measure: Systolic Blood Pressure, primaryOutcomes measure: Diastolic Blood Pressure, primaryOutcomes measure: Concentration of Blood Lipid, primaryOutcomes measure: Concentration of Blood Glucose, primaryOutcomes measure: Concentration of Blood Beta-Hydroxybutyrate, primaryOutcomes measure: Concentration of Blood Lactic Acid, primaryOutcomes measure: Concentration of Blood Insulin, primaryOutcomes measure: Reaction Time of Stroop Task, primaryOutcomes measure: Accuracy of Stroop Task, primaryOutcomes measure: Reaction Time of N-back Task, primaryOutcomes measure: Accuracy of N-back Task, primaryOutcomes measure: Cerebral Hemoglobin Concentration, secondaryOutcomes measure: Arousal Level, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06365944, orgStudyIdInfo id: CHUBX 2023/73, briefTitle: Concussion in French Non-professional Handball League : Efficiency of a Concussion Protocol, the White Card Process, acronym: PRECCOCE, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-20, primaryCompletionDateStruct date: 2026-04-20, completionDateStruct date: 2026-04-20, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: University Hospital, Bordeaux, class: OTHER, descriptionModule briefSummary: Sport related concussion is a major issue for many contact sports, such as Rugby, Football, Hockey and Handball. As a response, some federations like World Rugby set up a concussion protocol, that starts with the referee having the responsibility to issue a blue card when suspecting a concussed player and thus have him off the field for medical examination. The French handball federation (FFHB) as well as its concussion protocol called "Protocole carton blanc", in this study we aim to describe the efficiency of this protocol., conditionsModule conditions: Brain Concussion, conditions: Cerebral Concussion, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 3000, type: ESTIMATED, outcomesModule primaryOutcomes measure: Proportion, as a percentage, of participant declaring no medical care while being estimated at risk of having a concussion (assessed by answers to the questionnaire), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Bordeaux University Hospital, status: RECRUITING, city: Bordeaux, country: France, contacts name: Quentin LHUAIRE, role: CONTACT, geoPoint lat: 44.84044, lon: -0.5805, hasResults: False
protocolSection identificationModule nctId: NCT06365918, orgStudyIdInfo id: 2023-0836, secondaryIdInfos id: NCI-2024-03236, type: OTHER, domain: NCI-CTRP Clinical Registry, briefTitle: Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09-30, primaryCompletionDateStruct date: 2028-03-22, completionDateStruct date: 2030-03-22, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: M.D. Anderson Cancer Center, class: OTHER, descriptionModule briefSummary: To find the recommended dose of the investigational drug VG2025 that can be given intraperitoneally (given directly into the abdominal cavity) to participants with advanced solid tumors., conditionsModule conditions: Advanced Solid Tumor, conditions: Carcinomatosis, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 21, type: ESTIMATED, armsInterventionsModule interventions name: VG2025, outcomesModule primaryOutcomes measure: Safety and adverse events (AEs), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: MD Anderson Cancer Center, city: Houston, state: Texas, zip: 77030, country: United States, contacts name: Siqing Fu, MD,PHD, role: CONTACT, phone: 713-792-4318, email: siqingfu@mdanderson.org, contacts name: Siqing Fu, MD,PHD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 29.76328, lon: -95.36327, hasResults: False
protocolSection identificationModule nctId: NCT06365905, orgStudyIdInfo id: 23-011680, secondaryIdInfos id: NCI-2024-02550, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: 23-011680, type: OTHER, domain: Mayo Clinic in Rochester, briefTitle: Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2027-06-30, completionDateStruct date: 2027-06-30, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: This study evaluates if AI can be used with transvaginal ultrasound images for early detection of endometrial cancer or premalignant lesions., conditionsModule conditions: Endometrial Carcinoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: Non-Interventional Study, outcomesModule primaryOutcomes measure: Accuracy of artificial intelligence (AI) algorithm applied to transvaginal ultrasound (TVUS), eligibilityModule sex: FEMALE, minimumAge: 55 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic in Arizona, status: NOT_YET_RECRUITING, city: Scottsdale, state: Arizona, zip: 85259, country: United States, contacts name: Clinical Trials Referral Office, role: CONTACT, phone: 855-776-0015, email: mayocliniccancerstudies@mayo.edu, contacts name: Kristina A. Butler, M.D., M.S., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 33.50921, lon: -111.89903, locations facility: Mayo Clinic in Florida, status: NOT_YET_RECRUITING, city: Jacksonville, state: Florida, zip: 32224-9980, country: United States, contacts name: Clinical Trials Referral Office, role: CONTACT, phone: 855-776-0015, email: mayocliniccancerstudies@mayo.edu, contacts name: Christopher C. DeStephano, M.D., M.P.H., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.33218, lon: -81.65565, locations facility: Mayo Clinic in Rochester, status: RECRUITING, city: Rochester, state: Minnesota, zip: 55905, country: United States, contacts name: Clinical Trials Referral Office, role: CONTACT, phone: 855-776-0015, email: mayocliniccancerstudies@mayo.edu, contacts name: Gretchen E. Glaser, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06365879, orgStudyIdInfo id: CMAB007-003, briefTitle: To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-11-01, completionDateStruct date: 2026-05-01, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Taizhou Mabtech Pharmaceutical Co.,Ltd, class: INDUSTRY, descriptionModule briefSummary: This study is a multicenter, randomized, double-blind, positive parallel controlled phase III clinical trial to compare efficacy, immunogenicity, pharmacokinetics, pharmacodynamics and safety of omalizumab α(CMAB007) and Xolair® in patients with refractory chronic spontaneous urticaria, conditionsModule conditions: Chronic Spontaneous Urticaria, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 392, type: ESTIMATED, armsInterventionsModule interventions name: CMAB007, interventions name: Xolair, outcomesModule primaryOutcomes measure: Change From Baseline of the Itch Severity Score (ISS7) Score At Week 12, secondaryOutcomes measure: Change From Baseline of Urticaria Activity Score (UAS7) At Week 12, secondaryOutcomes measure: Change From Baseline of Number of Hives Score (NHS7) At Week 12, secondaryOutcomes measure: Time to ISS7 MID Response by Week 12, secondaryOutcomes measure: Percentage of Patients With UAS7≤6 at Week 12, secondaryOutcomes measure: Percentage of Patients With ISS7 Minimally Important Difference (MID) at Week 12, secondaryOutcomes measure: Change From Baseline of Urticaria Control Test (UCT) at Week 12, secondaryOutcomes measure: Percentage of Patients With UCT≥12 at Week 12, secondaryOutcomes measure: Percentage of Complete Controls (UCT=16) at Week 12, secondaryOutcomes measure: Change From Baseline of Dermatology Life Quality Index (DLQI) Score at Week 12, secondaryOutcomes measure: Percentage of Complete Responders (UAS7=0) at Week 12, secondaryOutcomes measure: Percentage of Angioedema-free Days From Week 4 to Week 12, secondaryOutcomes measure: Incidence of adverse events, secondaryOutcomes measure: Immunogenicity, secondaryOutcomes measure: AUC0-t, secondaryOutcomes measure: AUC0-inf, secondaryOutcomes measure: Half time, secondaryOutcomes measure: Cmax, secondaryOutcomes measure: Tmax, secondaryOutcomes measure: Clearance Rate, secondaryOutcomes measure: Apparent Volume of Distribution, secondaryOutcomes measure: Level of Total IgE and Free IgE, eligibilityModule sex: ALL, minimumAge: 15 Years, maximumAge: 75 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06365866, orgStudyIdInfo id: 2022-06-008B, briefTitle: Evaluate the Efficacy of Adding Intraluminal Brachytherapy After CCRT for Local-regional Thoracic Esophageal Cancer., statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-19, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Taipei Veterans General Hospital, Taiwan, class: OTHER_GOV, descriptionModule briefSummary: The purpose of this study is to observe the safety and effectiveness of the add-on of intraluminal brachytherapy with BRAXX esophageal brachytherapy applicator after definitive CCRT in patients with thoracic esophageal cancer., conditionsModule conditions: Esophageal Neoplasms, conditions: Head and Neck Neoplasms, conditions: Gastrointestinal Neoplasms, conditions: Digestive System Diseases, conditions: Digestive System Neoplasms, conditions: Esophageal Diseases, conditions: Neoplasms by Site, conditions: Gastrointestinal Diseases, conditions: Neoplasms, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Add-on treatment to standard treatment (fixed doses allowing dose reduction or dose delay according to the tolerability of individual patients); No control group., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: "BRAXX" Esophageal Brachytherapy Applicator., interventions name: Add-on of intraluminal brachytherapy, outcomesModule primaryOutcomes measure: To estimate the local control rate at primary tumor site., secondaryOutcomes measure: To estimate overall response rate., secondaryOutcomes measure: To estimate distant metastasis rate., secondaryOutcomes measure: To estimate progression-free survival rate., secondaryOutcomes measure: To estimate overall survival status., secondaryOutcomes measure: To estimate toxicity analysis., secondaryOutcomes measure: To estimate adverse event., eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Taipei Veterans General Hospital, status: RECRUITING, city: Taipei, zip: 11217, country: Taiwan, contacts name: Pin-I Huang, Ph.D., role: CONTACT, phone: +886 955-275-822, email: pihuang@vghtpe.gov.tw, contacts name: Pin-I Huang, Ph.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 25.04776, lon: 121.53185, hasResults: False